// App-Quantinova.ai

4507 : Long-term overall survival with nivolumab in previously treated patients with advanced renal cell carcinoma (aRCC) from phase I and II studies.

Researchers

Presenter

  • David F. McDermott

Principal Investigators

  • Robert J. Motzer

  • Michael B. Atkins

  • Elizabeth R. Plimack

  • Mario Sznol

  • Saby George

  • Charles G. Drake

  • Brian I. Rini

  • Toni K. Choueiri

  • Timothy Kuzel

  • Jeffrey Alan Sosman

  • David C. Smith

  • Ulka N. Vaishampayan

  • John D. Powderly

  • Suzanne Louise Topalian

  • Huanyu Zhao

  • Ian M. Waxman

  • Hans J. Hammers

Medical Centers

  • Beth Israel Deaconess Medical Center, Boston, MA

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Lombardi Comprehensive Cancer Center, Washington, DC

  • Fox Chase Cancer Center, Philadelphia, PA

  • Yale School of Medicine and Smilow Cancer Center, Yale-New Haven Hospital, New Haven, CT

  • Roswell Park Cancer Institute, Buffalo, NY

  • The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD

  • Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

  • Dana-Farber/Brigham and Women's Cancer Center, Boston, MA

  • Northwestern University, Feinberg School of Medicine, Chicago, IL

  • Vanderbilt-Ingram Cancer Center, Nashville, TN

  • University of Michigan Comprehensive Cancer Center, Ann Arbor, MI

  • Karmanos Cancer Institute, Detroit, MI

  • Carolina BioOncology Institute, Huntersville, NC

  • Bristol-Myers Sqiubb, Princeton, NJ

  • Bristol-Myers Sqiubb, Princeton, NJ

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Nephrology

Disease

  • Metastatic Renal Cell Cancer

Biomarkers

  • N/A

Drug/Treatment

  • Nivolumab

Outcome

  • N/A

Study Design

  • Randomized

  • Open Label

Phase

  • I

Study Id's

  • NCT00730639

  • NCT01354431

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved